Rasagiline

Rasagiline

SCHEMBL934443

C#CCN[C@@H]1CCc2ccccc21.CCCCCCCCCCCCc1ccc(S(=O)(=O)O)cc1

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MAOB

The experimentally established mechanism targets of Rasagiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MAOB known ✓ P27338 5/20 0.66
MAOA P21397 5/20 0.66
ACHE P22303 7/20 0.58
BCHE P06276 1/20 0.58
ADRA2B P18089 1/20 0.58
ADRA2C P18825 1/20 0.58
ADRA1A P35348 1/20 0.58
HTR6 P50406 1/20 0.58
TAOK1 Q7L7X3 4/20 0.47
TAOK3 Q9H2K8 4/20 0.47
EPHX2 P34913 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Rasagiline SCHEMBL2174799 0.84 MAOB (0.83) MAOAMAOBACHEBCHEADRA2B
Rasagiline SCHEMBL2173169 0.84 MAOB (0.78) MAOAMAOBACHEBCHEADRA2B
Rasagiline SCHEMBL934410 0.81 MAOB (0.70) MAOAMAOBACHEBCHEADRA2B
Rasagiline SCHEMBL5135147 0.81 MAOA (1.00) MAOAMAOBACHEBCHEADRA2B
Rasagiline SCHEMBL29469725 0.81 MAOA (1.00) MAOAMAOBACHEBCHEADRA2B
Rasagiline SCHEMBL2825094 0.81 MAOA (1.00) MAOAMAOBACHEBCHEADRA2B
Azilect SCHEMBL5960892 0.81 MAOA (1.00) MAOAMAOBACHEBCHEADRA2B
Rasagiline SCHEMBL2322409 0.81 MAOA (0.95) MAOAMAOBACHEBCHEADRA2B
Rasagiline SCHEMBL158439 0.81 MAOA (1.00) MAOAMAOBACHEBCHEADRA2B
Rasagiline SCHEMBL27489652 0.81 MAOA (0.95) MAOAMAOBACHEBCHEADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946482-B2 Salts of rasagiline and pharmaceutical preparations thereof RATIOPHARM GMBH (DE) 2015-02-03 US disclosed
EP-2451771-B1 SALTS OF RASAGILINE AND PHARMACEUTICAL PREPARATIONS THEREOF RATIOPHARM GMBH (DE) 2014-06-18 EP disclosed
US-20120142966-A1 SALTS OF RASAGILINE AND PHARMACEUTICAL PREPARATIONS THEREOF RATIOPHARM GMBH (DE) 2012-06-07 US disclosed
EP-2451771-A1 SALTS OF RASAGILINE AND PHARMACEUTICAL PREPARATIONS THEREOF Ratiopharm GmbH (DE) 2012-05-16 EP disclosed
WO-2011003938-A1 SALTS OF RASAGILINE AND PHARMACEUTICAL PREPARATIONS THEREOF RATIOPHARM GMBH (DE) 2011-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142966-A1 SALTS OF RASAGILINE AND PHARMACEUTICAL PREPARATIONS THEREOF RAB35, RAB27A, RAB5B MAOB 357/4885MAOA 257/4885ACHE 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.